COMPASS Pathways (CMPS) Stock Forecast & Price Target

Compass Pathways is well positioned fundamentally because its COMP360 program has moved from clinical proof-of-concept into regulatory and commercial execution, with the rolling NDA partially submitted, FDA already reviewing modules, and all remaining modules expected in 4Q26 ahead of a possible 1H27 launch. The investment case is strengthened by Phase 3 COMP006 data showing 39% of patients in the 25 mg arm achieved a clinically meaningful MADRS reduction at Week 6 and, on average, maintained it through at least Week 26, while 28% of non-remitted responders improved further after an additional dose. Financially, the company ended the quarter with $433.3 million of cash and runway into 2028, while its expanding network of more than 8,000 certified interventional psychiatry sites and over 1,000 partner sites suggests meaningful launch capacity.

Compass Pathways is a development-stage biotech with no diversified operating base, so its valuation depends heavily on COMP360 successfully clearing clinical, regulatory, and commercialization hurdles in treatment-resistant depression and PTSD. The company’s $433 million in cash and cash equivalents as of June 30 provides runway, but higher-than-expected operating expenses and a slower launch ramp underscore ongoing burn and execution risk. With a DCF-driven view still relying on a 95% success probability for TRD and 75% for PTSD, the stock remains vulnerable to clinical setbacks, dilution, reimbursement pressure, and competition.